title: Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma.
abstract: The goal of this study was to evaluate the anti-tumour activity and toxicoses of vinorelbine as a palliative rescue therapy for dogs with primary urinary bladder carcinoma. Thirteen dogs refractory to prior chemotherapeutics and one dog naïve to chemotherapeutic treatment were enrolled. Vinorelbine (15 mg m(-2) IV) was administered intravenously along with concurrent oral anti-inflammatory drugs, if tolerated. A median of six doses of vinorelbine (range: 1-16) was administered. Two dogs (14%) had partial responses, and eight (57%) experienced stable disease. Subjective improvement in clinical signs was noted in 11 dogs (78%). Adverse events were mild and primarily haematological in nature. Median time to progression was 93 days (range: 20-239 days). Median survival time for all dogs was 187 days; median survival for 13 pre-treated dogs was 207 days. Vinorelbine may have utility in the management of canine primary urinary bladder carcinoma and should be evaluated in a prospective study.
authors: Department of Small Animal Medicine & Surgery, University of Georgia, College of Veterinary Medicine, Athens, GA, USA.
authors: M E
authors: ME
authors: Kaye
authors: The Animal Cancer Center, Veterinary Teaching Hospital, Colorado State University, Collins, CO, USA.
authors: D H
authors: DH
authors: Thamm
authors: The Animal Cancer Center, Veterinary Teaching Hospital, Colorado State University, Collins, CO, USA.
authors: K
authors: K
authors: Weishaar
authors: Department of Small Animal Medicine & Surgery, University of Georgia, College of Veterinary Medicine, Athens, GA, USA.|Current address: Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush Campus, Midlothian EH25 9RG, UK.
authors: J A
authors: JA
authors: Lawrence
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality; D004285:Dogs; D004334:Drug Administration Schedule / Q000662:veterinary; D058492:Drug Repositioning / Q000662:veterinary; D005260:Female; D008297:Male; D016019:Survival Analysis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D000077235:Vinorelbine
keywords: canine; oncology; quality of life; urogenital medicine